{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002661","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.792687+00:00","generated_at":"2026-06-07T02:04:16.448608+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lyra reports BEACON Phase 2 smell-loss data: 0.87 improvement at week 24 (p=0.026)","bullets":["BEACON Phase 2 trial: 0.87 improvement in smell loss vs control at week 24 (p=0.026) in patients with impaired smell at baseline.","Data filed in corporate presentation posted Jan 8, 2024; subset analysis shows statistically significant benefit.","No safety or additional efficacy details disclosed; further development plans not specified.","Lyra is a clinical-stage biotech focused on chronic rhinosinusitis therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002661","json":"https://secwatch.observer/filing/0000950170-24-002661.json","markdown":"https://secwatch.observer/filing/0000950170-24-002661.md","text":"https://secwatch.observer/filing/0000950170-24-002661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024002661/0000950170-24-002661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024002661/lyra-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:04:16.448608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}